Principal Financial Group
PTGX icon

Principal Financial Group’s Protagonist Therapeutics PTGX Stock Holding History

Principal Financial Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.2M Buy
385,262
+17,440
+5% +$1.82M 0.02% 547
2026
Q1 		$38.8M Buy
367,822
+19,890
+6% +$1.76M 0.02% 564
2025
Q4 		$30.4M Buy
347,932
+21,844
+7% +$1.79M 0.02% 656
2025
Q3 		$21.7M Sell
326,088
-4,046
-1% -$230K 0.01% 822
2025
Q2 		$18.2M Sell
330,134
-16,961
-5% -$814K 0.01% 886
2025
Q1 		$16.8M Buy
347,095
+9,286
+3% +$389K 0.01% 949
2024
Q4 		$13M Buy
337,809
+16,977
+5% +$740K 0.01% 1134
2024
Q3 		$14.4M Buy
320,832
+310,804
+3,099% +$12.6M 0.01% 1050
2024
Q2 		$347K Sell
10,028
-4,341
-30% -$127K ﹤0.01% 2033
2024
Q1 		$416K Sell
14,369
-60
-0.4% -$1.63K ﹤0.01% 2029
2023
Q4 		$331K Sell
14,429
-542
-4% -$9.48K ﹤0.01% 2036
2023
Q3 		$250K Buy
14,971
+1,068
+8% +$20.7K ﹤0.01% 2107
2023
Q2 		$384K Buy
13,903
+380
+3% +$9.51K ﹤0.01% 2012
2023
Q1 		$311K Buy
13,523
+1,785
+15% +$30K ﹤0.01% 2078
2022
Q4 		$128K Buy
11,738
+1,389
+13% +$11.7K ﹤0.01% 2263
2022
Q3 		$87K Buy
+10,349
New +$97.9K ﹤0.01% 2355
2022
Q1 		– Sell
-7,607
Closed -$260K – 2591
2021
Q4 		$260K Buy
+7,607
New +$240K ﹤0.01% 2288
2021
Q3 		– Sell
-16,540
Closed -$743K – 2613
2021
Q2 		$743K Buy
16,540
+8,364
+102% +$276K ﹤0.01% 2116
2021
Q1 		$212K Buy
+8,176
New +$207K ﹤0.01% 2369

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Principal Financial Group's PTGX Position: Q2 2026 in Review

Principal Financial Group increased its Protagonist Therapeutics (PTGX) stake by 4.7% in Q2 2026, buying an estimated $1.82M and bringing the position to 385,262 shares worth $47.2M. The position accounts for 0.02% of the portfolio, ranked #547.

Principal Financial Group first reported a position in PTGX in Q1 2021 and has held it in 19 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Principal Financial Group held 385,262 shares of Protagonist Therapeutics worth $47.2M as of Q2 2026.
  • Principal Financial Group bought 17,440 Protagonist Therapeutics shares in Q2 2026, an estimated $1.82M.
  • Protagonist Therapeutics made up 0.02% of Principal Financial Group's portfolio in Q2 2026, its #547 holding.
  • Principal Financial Group first reported a position in Protagonist Therapeutics in Q1 2021 and has held it in 19 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.